Logo image
Back
Cancer-testis antigens (CTAs) in lung cancer
Journal article   Peer reviewed

Cancer-testis antigens (CTAs) in lung cancer

Chitrali Talele, Chintan Aundhia, Dipali Talele, Niyati Shah, Mamta Kumari, Surya Nath Pandey, Nardev Singh, Gaurav Gupta, Moayad Al Shahwan and Kamal Dua
Clinica chimica acta, Vol.579, p.120687
15/01/2026
DOI: https://doi.org/10.1016/j.cca.2025.120687
PMID: 41176051
Appears in  Recent Faculty of Health Publications

Metrics

1 Record Views
Article has an altmetric score of 1

See more details

1 readers on Mendeley

Abstract

Biomarkers Cancer/Testis Antigens Diagnosis Lung Cancer Treatment
The predominant cause of cancer-related death worldwide is lung cancer. Poor survival rates are mainly due to late diagnosis due to the lack of sensitive and specific biomarkers and analytical tools. In this review, we examine the use of cancer-testis antigens (CTAs) as potential biomarkers due to their increased expression in malignancy. For example, the diagnostic potential of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) autoantibodies was low for sensitivity (48.3%) but higher for specificity (90.9%) in small cell lung cancer (SCLC). In contrast, A-kinase anchoring protein 4 (AKAP4) peripheral blood mononuclear cell (PBMC) quantitative polymerase chain reaction (qPCR) was 92.8% (sensitivity) and 92.6%, (specificity) in non-small cell lung cancer (NSCLC). We assess existing knowledge regarding CTAs and compare their effectiveness vs other markers such as NY-ESO-1, melanoma-associated antigen A (MAGE-A), sperm-associated antigen 9 (SPAG9), AKAP4, X antigen family member 1 (XAGE-1) and B-cell receptor-associated protein 31 (BCAP31). We also discuss the incorporation of CTA testing in lung cancer diagnostic workflows with focus on its analytical performance, preanalytical factors as well as comparative value vs existing markers. Finally, we outline the role of CTAs as companion diagnostics in immunotherapy and targeted treatment plans, and indicate the main challenges and research priorities towards the clinical translation of CTAs. •CTAs enable lab-ready assays for lung cancer detection and monitoring.•Multiplex CTA panels improve sensitivity across tumour heterogeneity.•Prognostic CTAs (e.g., MAGE-A, BCAP31) stratify risk and outcomes.•Clinical translation demands rigorous analytical validation and EQA.•Liquid-biopsy integration supports minimally invasive ongoing care.

Details

Logo image